221 related articles for article (PubMed ID: 35866293)
1. Identification of prediagnostic metabolites associated with prostate cancer risk by untargeted mass spectrometry-based metabolomics: A case-control study nested in the Northern Sweden Health and Disease Study.
Östman JR; Pinto RC; Ebbels TMD; Thysell E; Hallmans G; Moazzami AA
Int J Cancer; 2022 Dec; 151(12):2115-2127. PubMed ID: 35866293
[TBL] [Abstract][Full Text] [Related]
2. Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study.
Röhnisch HE; Kyrø C; Olsen A; Thysell E; Hallmans G; Moazzami AA
BMC Med; 2020 Jul; 18(1):187. PubMed ID: 32698845
[TBL] [Abstract][Full Text] [Related]
3. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
[TBL] [Abstract][Full Text] [Related]
4. Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification.
Zoni E; Minoli M; Bovet C; Wehrhan A; Piscuoglio S; Ng CKY; Gray PC; Spahn M; Thalmann GN; Kruithof-de Julio M
BMC Cancer; 2019 Dec; 19(1):1216. PubMed ID: 31842810
[TBL] [Abstract][Full Text] [Related]
5. Plasma metabolites associated with type 2 diabetes in a Swedish population: a case-control study nested in a prospective cohort.
Shi L; Brunius C; Lehtonen M; Auriola S; Bergdahl IA; Rolandsson O; Hanhineva K; Landberg R
Diabetologia; 2018 Apr; 61(4):849-861. PubMed ID: 29349498
[TBL] [Abstract][Full Text] [Related]
6. Exploration of circulating metabolic signature of erythrodermic psoriasis based on LC-MS metabolomics.
Guo L; Wu C; Song B; Jin HZ
Exp Dermatol; 2024 May; 33(5):e15103. PubMed ID: 38794829
[TBL] [Abstract][Full Text] [Related]
7. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
[TBL] [Abstract][Full Text] [Related]
8. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
Front Oncol; 2021; 11():730638. PubMed ID: 34722271
[TBL] [Abstract][Full Text] [Related]
9. Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS.
Lu Y; Wang Y; Ong CN; Subramaniam T; Choi HW; Yuan JM; Koh WP; Pan A
Diabetologia; 2016 Nov; 59(11):2349-2359. PubMed ID: 27514531
[TBL] [Abstract][Full Text] [Related]
10. Plasma metabolites associated with healthy Nordic dietary indexes and risk of type 2 diabetes-a nested case-control study in a Swedish population.
Shi L; Brunius C; Johansson I; Bergdahl IA; Lindahl B; Hanhineva K; Landberg R
Am J Clin Nutr; 2018 Sep; 108(3):564-575. PubMed ID: 30060042
[TBL] [Abstract][Full Text] [Related]
11. The potential role of fatty acids in prostate cancer determined by GC-MS analysis of formalin-fixed paraffin-embedded tissue samples.
Buszewska-Forajta M; Raczak-Gutknecht J; Artymowicz M; Wesołowski W; Buczkowski K; Iżycka-Świeszewska E; Markuszewski MJ
J Pharm Biomed Anal; 2021 Mar; 196():113907. PubMed ID: 33497978
[TBL] [Abstract][Full Text] [Related]
12. Serum metabolomics study of women with different annual decline rates of anti-Müllerian hormone: an untargeted gas chromatography-mass spectrometry-based study.
Moslehi N; Mirmiran P; Marzbani R; Rezadoost H; Mirzaie M; Azizi F; Tehrani FR
Hum Reprod; 2021 Feb; 36(3):721-733. PubMed ID: 33320198
[TBL] [Abstract][Full Text] [Related]
13. A nested case-control study of untargeted plasma metabolomics and lung cancer among never-smoking women within the prospective Shanghai Women's Health Study.
Rahman ML; Shu XO; Jones DP; Hu W; Ji BT; Blechter B; Wong JYY; Cai Q; Yang G; Gao YT; Zheng W; Rothman N; Walker D; Lan Q
Int J Cancer; 2024 Aug; 155(3):508-518. PubMed ID: 38651675
[TBL] [Abstract][Full Text] [Related]
14. Plasma Metabolomic Profiles and Risk of Advanced and Fatal Prostate Cancer.
Wang Y; Jacobs EJ; Carter BD; Gapstur SM; Stevens VL
Eur Urol Oncol; 2021 Feb; 4(1):56-65. PubMed ID: 31378665
[TBL] [Abstract][Full Text] [Related]
15. [Plasma metabolomics in a deep vein thrombosis rat model based on ultra-high performance liquid chromatography-electrostatic field orbitrap high resolution mass spectrometry].
Gu Y; Zang P; Li J; Yan Y; Wang J
Se Pu; 2022 Aug; 40(8):736-745. PubMed ID: 35903841
[TBL] [Abstract][Full Text] [Related]
16. LC-MS-based untargeted metabolomics reveals the mechanism underlying prostate damage in a type 2 diabetes mouse model.
Qi R; Kang SS; Pei Y; Liu M; Zhou Y; Guan B; Zhang X; Li Z; Cao F
Reprod Biol; 2023 Dec; 23(4):100811. PubMed ID: 37660522
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Metabolomics and Lipidomics Profiling of Prostate Cancer Tissue Reveals Metabolic Dysregulations Associated with Disease Development.
Lima AR; Carvalho M; Aveiro SS; Melo T; Domingues MR; Macedo-Silva C; Coimbra N; Jerónimo C; Henrique R; Bastos ML; Guedes de Pinho P; Pinto J
J Proteome Res; 2022 Mar; 21(3):727-739. PubMed ID: 34813334
[TBL] [Abstract][Full Text] [Related]
18. Rapid Prostate Cancer Noninvasive Biomarker Screening Using Segmented Flow Mass Spectrometry-Based Untargeted Metabolomics.
Pinto FG; Mahmud I; Harmon TA; Rubio VY; Garrett TJ
J Proteome Res; 2020 May; 19(5):2080-2091. PubMed ID: 32216312
[TBL] [Abstract][Full Text] [Related]
19. Prospective serum metabolomic profiling of lethal prostate cancer.
Huang J; Mondul AM; Weinstein SJ; Derkach A; Moore SC; Sampson JN; Albanes D
Int J Cancer; 2019 Dec; 145(12):3231-3243. PubMed ID: 30779128
[TBL] [Abstract][Full Text] [Related]
20. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
